
    
      The study will start with an accelerated-titration dose escalation scheme, enrolling 1
      patient per cohort for the first 2 cohorts with expansion to 3 patients in the event of Grade
      â‰¥ 2 treatment-emergent adverse event (TEAE) or dose limiting toxicity (DLT) possibly,
      probably, or definitely related to the study drug. After the first 2 cohorts, the study will
      then proceed to a 3+3 design, with enrollment of 3 patients per cohort and expansion to 6
      patients in the event of a DLT.
    
  